INTERNATIONAL PATENT: IMMUSE THERAPEUTICS, INC., 주식회사 이뮤즈테라퓨틱스 FILES APPLICATION FOR "HETEROCYCLIC COMPOUND AS LRRK2 INHIBITOR"

GENEVA, Nov. 25 -- IMMUSE THERAPEUTICS, INC. (7F, 30, Gasan digital 2-roGeumcheon-guSeoul 08592), 주식회사 이뮤즈테라퓨틱스 (서울특별시금천구가산디지털2로 30, 7층) filed a patent application (PCT/KR2025/006517) for "HETEROCYCLIC COMPOUND AS LRRK2 INHIBITOR" on May 14, 2025. With publication no. WO/2025/239667, the details related to the patent application was published on Nov 20, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): MIN, ...